Daniel Goldstein

Daniel Goldstein MD is a medical oncologist and internist at Rabin Medical Center in Israel, as well as a senior lecturer in Medical Oncology at Tel Aviv University. He is also the medical director of drug and technology policies, in the community division of Clalit Health Services. In this role, he is responsible for developing policies that impact 4 million insurees. His clinical focus is treating patients with genitourinary cancers. He received his medical training at Leeds University, UK, followed by a residency in internal medicine at Montefiore Medical Center in New York and a fellowship in hematology and medical oncology at Emory University, Atlanta. His area of research is in the economics of cancer care both in the USA and around the world, focusing on cost-effectiveness, budget impact and affordability. This led to his appointment as an adjunct associate professor in the Department of Health Policy and Management, Gillings School of Public Health, University of North Carolina. His work has been reported in major news outlets such as the Wall Street Journal, Washington Post, and the Economist. His research also focusses on pharmacologic opportunities to reduce cancer drug expenditure with dose adjustments, while maintaining health outcomes.